Literature DB >> 18958580

Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

M Dalla Vestra1, N Simioni, A Masiero.   

Abstract

Evidence from recent studies indicates that in patients with diabetic nephropathy combined therapy with ACE inhibitors (ACEI) and AT1-receptor antagonists (ARB) results in more complete blockade of the renin-angiotensin-aldosterone system (RAS) than monotherapy, and reduces proteinuria. Most of these trials, however, had short follow-up, included a small number of patients, and were heterogeneous, so the opportunity to start this treatment in these patients remains unclear. This review summarizes the results of these studies, describing the renal effects of dual RAS blockade in both type 1 and type 2 diabetic patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18958580     DOI： 10.1007/s11255-008-9490-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  53 in total

1.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Authors:  Kasper Rossing; Per K Christensen; Berit R Jensen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

Review 2.  Angiotensin as inducer of plasminogen activator inhibitor-1 and fibrosis.

Authors:  L J Ma; A B Fogo
Journal:  Contrib Nephrol       Date:  2001       Impact factor: 1.580

3.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 4.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

5.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

Review 8.  Inhibition of the renin-angiotensin system and chronic kidney disease.

Authors:  Kostas C Siamopoulos; Rigas G Kalaitzidis
Journal:  Int Urol Nephrol       Date:  2008-08-14       Impact factor: 2.370

9.  Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Authors:  Yoshiyuki Furumatsu; Yasuyuki Nagasawa; Kodo Tomida; Satoshi Mikami; Tetsuya Kaneko; Noriyuki Okada; Yoshiharu Tsubakihara; Enyu Imai; Tatsuya Shoji
Journal:  Hypertens Res       Date:  2008-01       Impact factor: 3.872

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245
View more
  4 in total

Review 1.  Direct renin inhibitors: ONTARGET for success?

Authors:  Yasmin Pasha; Paul Gusbeth-Tatomir; Adrian Covic; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2009-03-19       Impact factor: 2.370

Review 2.  Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 3.  Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Authors:  Terry K W Ma; Kevin K H Kam; Bryan P Yan; Yat-Yin Lam
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.

Authors:  D Banerjee; P Winocour; T A Chowdhury; P De; M Wahba; R Montero; D Fogarty; A H Frankel; J Karalliedde; P B Mark; D C Patel; A Pokrajac; A Sharif; S Zac-Varghese; S Bain; I Dasgupta
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.